Assays Used to Monitor Infliximab Are Similarly Effective for Biosimilars SB2, CT-P13
February 28th 2020The quantitative comparison study compared 4 different, commercially available enzyme-linked immunosorbent assays used in therapeutic drug monitoring to detect drug concentration and antibodies to infliximab in samples of drug diluted in serum.
Study: Adalimumab Plus Hydroxychloroquine Leads to Hair Regrowth in Lichen Planopilaris
February 27th 2020Lichen planopilaris (LPP) is a type of scarring hair loss that occurs when lichen plaus, a relatively common inflammatory skin disease, affects areas of skin where hair grows. It destroys the hair follicle and replaces it with scarring, resulting in permanent hair loss. LPP’s causes and pathology are unknown.
Appeals Court Rules J&J Must Face Infliximab Antitrust Suit Brought by Walgreens, Kroger
February 26th 2020Antitrust claims are a product of federal statute, said the Third Circuit Court of Appeals, in reinstating a Walgreens and Kroger antitrust lawsuit against J&J over its branded infliximab, Remicade.
Researchers Suspect Link Between Missing Gut Microbes, Ulcerative Colitis
February 25th 2020The study compared the stool samples of patients with ulcerative colitis (UC) with patients with familial adenomatous polyposis. Both groups may have colectomies, but only the patients with UC have inflammation that may return even after surgery.
FDA Launches Searchable Database Intended to Replace Static Purple Book Lists
February 24th 2020Ultimately, the Purple Book is supposed to include all Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER) regulated products, including transition biological products.
2019 Saw Mounting Evidence to Support Nonmedical Switching, Review Article Says
February 21st 2020A recent year-in-review article outlines studies published in 2019 about nonmedical switching from originator biologics to biosimilars in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
Looking Forward: 2020 Expected to Be Major Year for Biosimilar Market
February 21st 2020Although the US biosimilar market had a slow start, the booming industry in Europe shows the potential for the market here. However, in order to level the playing field, more policy changes and legislation are needed to prevent originator products from crowding out competitors.
AbbVie: Next-Generation Skyrizi and Rinvoq Are Showing Traction in Humira Space
February 21st 2020Pharmaceutical giant AbbVie reports strong revenues for next-generation products the company hopes will provide fill-in revenue as Humira (adalimumab) sales decline and more biosimilars to the blockbuster arthritis drug enter the market.
No Higher Risk of Cancer for Patients With Psoriasis Treated With Biologics, Analysis Finds
February 19th 2020The review found no increased risk of cancer when looking at both keratinocyte cancer and lymphomas in patients on biologics vs conventional therapy. Overall, however, patients with psoriasis appear to have a slightly increased risk of certain cancers.
Office of Pharmaceutical Quality Report: Key Deadline Looming for BPCIA
February 18th 2020The Office of Pharmaceutical Quality, charged with strengthening and building public trust in the US supply of medicine, notes that March 23, 2020, will mark a key turning point in the way that many biologics are licensed.
Follow-on Insulin Glargine, Generic Glatiramer Illustrate Medicaid Drug Rebate Issue, Study Says
February 17th 2020Which Medicaid plans benefit the most from the current drug rebate structure and are incentivized to prescribe branded prescriptions? Researchers used the issue of follow-on insulin glargine as well as glatiramer acetate to find out.
Study Finds Similar Pharmacokinetics, Safety of SB4 in 2 Self-Delivery Methods
February 13th 2020Previous studies demonstrating equivalence of SB4 to etanercept in pharmacokinetics and safety have used pre-filled syringes, but these devices may be difficult for some patients to use if they have reduced hand dexterity due to the challenges of living with rheumatoid arthritis.
What Are the Factors for Starting Anti-TNF Inhibitor Biosimilars in RA and AS?
February 11th 2020The study aimed to provide insight into the real-world patterns of biosimilar initiation in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in Korea by identifying patient characteristics and other factors associated with starting biosimilars using a logistic regression model.
Updated EULAR RA Treatment Recommendations Address Patient Concerns, Recent Developments
February 9th 2020Updated guidelines from the European League Against Rheumatism (EULAR), based on new evidence and a review of the literature from 2016 to 2018, address recommendations on the use of disease-modifying antirheumatic drugs and glucocorticoids to treat patients with rheumatoid arthritis (RA). Included is guidance on mono- and combination therapies, treatment strategies, and tapering treatment.
FDA Hopes to Accelerate Biosimilar Supplement Reviews
February 7th 2020The agency will now review and act on original 351(k) biologics license application (BLA) supplements with clinical data within a 6-month time frame. Originally, such supplements had a 10-month goal date for review. In addition, applicants can now request the FDA refrain from taking action on supplements of 351(k) BLAs before a certain date.
Eye on Pharma: Phase 3 Trial of Bio-Thera Solutions' BAT1706 Yields Positive Results
February 6th 2020Bio-Thera Solutions announced that a phase 3 clinical trial comparing the efficacy and safety of its bevacizumab biosimilar, BAT1706, to the reference product (Avastin), returned positive top-line results.
Reference-Based Drug Pricing Shifts Mix of Therapies, Lowers Prices Paid, Study Finds
February 5th 2020Reference pricing may shift the mix of drugs dispensed from those offering the highest rebates to pharmacy benefit managers to those offering the lowest prices to employers and employees, according to a new study published Wednesday.
FDA, FTC Pledge Close Cooperation to Create Biosimilar Competition
February 4th 2020The FDA and the Federal Trade Commission (FTC) will work more closely to support a more competitive market for biosimilars and interchangeable products. In addition, the FDA published draft guidance for industry about how to advertise and promote biologic products truthfully and announced a public workshop.